GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medclair AB (NGM:MCLR) » Definitions » Debt-to-EBITDA

Medclair AB (NGM:MCLR) Debt-to-EBITDA : 0.05 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Medclair AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medclair AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.27 Mil. Medclair AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Medclair AB's annualized EBITDA for the quarter that ended in Mar. 2024 was kr4.90 Mil. Medclair AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.05.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Medclair AB's Debt-to-EBITDA or its related term are showing as below:

NGM:MCLR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -9.56   Med: -1.36   Max: 1.88
Current: 0.13

During the past 9 years, the highest Debt-to-EBITDA Ratio of Medclair AB was 1.88. The lowest was -9.56. And the median was -1.36.

NGM:MCLR's Debt-to-EBITDA is ranked better than
85.88% of 425 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs NGM:MCLR: 0.13

Medclair AB Debt-to-EBITDA Historical Data

The historical data trend for Medclair AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medclair AB Debt-to-EBITDA Chart

Medclair AB Annual Data
Trend Apr15 Apr16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -9.56 -2.78 -0.18 1.88 0.13

Medclair AB Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 -0.15 0.06 -0.48 0.05

Competitive Comparison of Medclair AB's Debt-to-EBITDA

For the Medical Devices subindustry, Medclair AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medclair AB's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medclair AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Medclair AB's Debt-to-EBITDA falls into.



Medclair AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medclair AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.39 + 0) / 3.125
=0.12

Medclair AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.266 + 0) / 4.904
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Medclair AB  (NGM:MCLR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Medclair AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Medclair AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Medclair AB (NGM:MCLR) Business Description

Traded in Other Exchanges
N/A
Address
Box 3113, Stockholm, SWE, 103 62
Medclair Invest AB is a research and development company with leading-edge expertise in measurement, collection and destruction of Nitrous Oxide. The customers are found in a number of industries such as Obstetrics, Pediatrics, Emergency departments and Dental Care facilities. The business is operational on a global scale.

Medclair AB (NGM:MCLR) Headlines

No Headlines